ELFABRIO
(Pegunigalsidase alfa)PreclinicalProtein / enzyme
Chiesi Farmaceutici S.p.A.ELFABRIO is one of 21 biologic programs targeting Fabry Disease. It is currently in Preclinical.
1
Indications
7
Total Trials
4
Active Trials
20
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Fabry Disease
#DrugCompanyPhaseTrials
1Fabrazyme (agalsidase Beta)
SanofiApproved
Active Comparator
ModernaPhase 3
Venglustat
SanofiPhase 3
Agalsidase
SanofiApproved
Farxiga
AstraZenecaPhase 2
Recombinant Alpha-Galactosidase a
AAssistance Publique - Hôpitaux de Paris
Approved
Replagal
TakedaPhase 3
Galafold
AAmicus Therapeutics
Phase 3
Agalsidase Alfa
TakedaPhase 3
Migalastat Hcl
AAmicus Therapeutics
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Fabry Disease6 trials
Regulatory
FDA Approval Timeline[4]
May 9, 2023
ELFABRIO
BLA BLA761161
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pegunigalsidase alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Preclinical[1]
- Company